A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis; OASIS-1

Press/Media: Press / Media

Period2018 Oct 2

Media coverage

1

Media coverage